North America Pharmacovigilance and Drug Safety Software Market 2021-2031 by Functionality (Adverse Event Reporting, Drug Safety Audits, Issue Tracking, Fully Integrated), Clinical Phase (Pre-clinical, Phase I-IV), Method, Delivery Mode (On-premise, On-demand), Indication, End User (Pharma and Biotech Companies, CROs, BPOs, Others), and Country: Trend Forecast and Growth Opportunity

July 2022 | 111 pages | ID: NBEF4F27C189EN
GMD Research

Abstracts

North America pharmacovigilance and drug safety software market is projected to grow by 6.7% annually in the forecast period and reach $158.6 million by 2031, driven by the increasing prevalence of chronic diseases due to the aging population, the growing drug discovery pipelines, increase in incidence of adverse drug reactions (ADR), more stringent regulatory guidelines for drug safety, and the increasing adoption of AI and cloud technologies in PV software and solutions.

Highlighted with 23 tables and 56 figures, this 111-page report “North America Pharmacovigilance and Drug Safety Software Market 2021-2031 by Functionality (Adverse Event Reporting, Drug Safety Audits, Issue Tracking, Fully Integrated), Clinical Phase (Pre-clinical, Phase I-IV), Method, Delivery Mode (On-premise, On-demand), Indication, End User (Pharma and Biotech Companies, CROs, BPOs, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America pharmacovigilance and drug safety software market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America pharmacovigilance and drug safety software market in every aspect of the classification from perspectives of Functionality, Clinical Phase, Method, Delivery Mode, Indication, End User, and Country.

Based on Functionality, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Adverse Event Reporting Software
• Drug Safety Audits Software
• Issue Tracking Software
• Fully Integrated Software

Based on Clinical Phase, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

By Method, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

By Delivery Mode, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• On-premise Delivery
• On-demand Delivery

By Indication, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Oncology
• Respiratory Disorders
• Cardiology
• Neurology
• Immunology
• Pain Management
• Other Indications

By End Users, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Business Process Outsourcing Firms (BPOs)
• Other End Users

Geographically, the following national/local markets are fully investigated:

• U.S.
• Canada
• Mexico

For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Functionality, Delivery Mode and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Selected Key Players:

Ab Cube

Accenture PLC

ArisNorth America LLC

Cognizant Technology Solutions Corporation

Ennov Solutions Inc.

Extedo GmbH

Honeywell International Inc. (Sparta Systems Inc.)

IQVIA Inc.

Max Application

Oracle Corporation

Sarjen Systems Pvt. Ltd.

United BioSource LLC

Veeva Systems Inc.

Wipro Limited

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on World Economy
  2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF NORTH AMERICA MARKET BY FUNCTIONALITY

3.1 Market Overview by Functionality
3.2 Adverse Event Reporting Software
3.3 Drug Safety Audits Software
3.4 Issue Tracking Software
3.5 Fully Integrated Software

4 SEGMENTATION OF NORTH AMERICA MARKET BY CLINICAL PHASE

4.1 Market Overview by Clinical Phase
4.2 Pre-clinical
4.3 Phase I
4.4 Phase II
4.5 Phase III
4.6 Phase IV

5 SEGMENTATION OF NORTH AMERICA MARKET BY METHOD

5.1 Market Overview by Method
5.2 Spontaneous Reporting
5.3 Intensified ADR Reporting
5.4 Targeted Spontaneous Reporting
5.5 Cohort Event Monitoring
5.6 EHR Mining

6 SEGMENTATION OF NORTH AMERICA MARKET BY DELIVERY MODE

6.1 Market Overview by Delivery Mode
6.2 On-premise Delivery
6.3 On-demand Delivery

7 SEGMENTATION OF NORTH AMERICA MARKET BY INDICATION

7.1 Market Overview by Indication
7.2 Oncology
7.3 Respiratory Disorders
7.4 Cardiology
7.5 Neurology
7.6 Immunology
7.7 Pain Management
7.8 Other Indications

8 SEGMENTATION OF NORTH AMERICA MARKET BY END USER

8.1 Market Overview by End User
8.2 Pharmaceutical and Biotechnology Companies
8.3 Contract Research Organizations (CROs)
8.4 Business Process Outsourcing Firms (BPOs)
8.5 Other End Users

9 NORTH AMERICA MARKET 2021-2031 BY COUNTRY

9.1 Overview of North America Market
9.2 U.S.
9.3 Canada
9.4 Mexico

10 COMPETITIVE LANDSCAPE

10.1 Overview of Key Vendors
10.2 New Product Launch, Partnership, Investment, and M&A
10.3 Company Profiles
Ab Cube
Accenture PLC
ArisNorth America LLC
Cognizant Technology Solutions Corporation
Ennov Solutions Inc.
Extedo GmbH
Honeywell International Inc. (Sparta Systems Inc.)
IQVIA Inc.
Max Application
Oracle Corporation
Sarjen Systems Pvt. Ltd.
United BioSource LLC
Veeva Systems Inc.
Wipro Limited
RELATED REPORTS

List Of Tables

LIST OF TABLES

Table 1. Snapshot of North America Pharmacovigilance and Drug Safety Software Market in Balanced Perspective, 2021-2031
Table 2. World Economic Outlook, 2021-2031
Table 3. World Economic Outlook, 2021-2023
Table 4. Main Product Trends and Market Opportunities in North America Pharmacovigilance and Drug Safety Software Market
Table 5. North America Pharmacovigilance and Drug Safety Software Market by Functionality, 2021-2031, $ mn
Table 6. North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase, 2021-2031, $ mn
Table 7. North America Pharmacovigilance and Drug Safety Software Market by Method, 2021-2031, $ mn
Table 8. North America Pharmacovigilance and Drug Safety Software Market by Delivery Mode, 2021-2031, $ mn
Table 9. North America Pharmacovigilance and Drug Safety Software Market by Indication, 2021-2031, $ mn
Table 10. North America Pharmacovigilance and Drug Safety Software Market by End User, 2021-2031, $ mn
Table 11. North America Pharmacovigilance and Drug Safety Software Market by Country, 2021-2031, $ mn
Table 12. U.S. Pharmacovigilance and Drug Safety Software Market by Functionality, 2021-2031, $ mn
Table 13. U.S. Pharmacovigilance and Drug Safety Software Market by Delivery Mode, 2021-2031, $ mn
Table 14. U.S. Pharmacovigilance and Drug Safety Software Market by End User, 2021-2031, $ mn
Table 15. Canada Pharmacovigilance and Drug Safety Software Market by Functionality, 2021-2031, $ mn
Table 16. Canada Pharmacovigilance and Drug Safety Software Market by Delivery Mode, 2021-2031, $ mn
Table 17. Canada Pharmacovigilance and Drug Safety Software Market by End User, 2021-2031, $ mn
Table 18. Mexico Pharmacovigilance and Drug Safety Software Market by Functionality, 2021-2031, $ mn
Table 19. Mexico Pharmacovigilance and Drug Safety Software Market by Delivery Mode, 2021-2031, $ mn
Table 20. Mexico Pharmacovigilance and Drug Safety Software Market by End User, 2021-2031, $ mn
Table 21. Ab Cube: Company Snapshot
Table 22. Ab Cube: Business Segmentation
Table 23. Ab Cube: Product Portfolio

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031
Figure 4. North America Pharmacovigilance and Drug Safety Software Market, 2021-2031, $ mn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of North America Pharmacovigilance and Drug Safety Software Market
Figure 7. Percentage of Trial Participants by Country, 2015-2019
Figure 8. World Drug Discovery Market, 2019-2030, $ mn
Figure 9. Primary Restraints and Impact Factors of North America Pharmacovigilance and Drug Safety Software Market
Figure 10. Investment Opportunity Analysis
Figure 11. Porter’s Fiver Forces Analysis of North America Pharmacovigilance and Drug Safety Software Market
Figure 12. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by Functionality, 2021-2031, % of Revenue
Figure 13. North America Addressable Market Cap in 2022-2031 by Functionality, Value ($ mn) and Share (%)
Figure 14. North America Pharmacovigilance and Drug Safety Software Market by Functionality: Adverse Event Reporting Software, 2021-2031, $ mn
Figure 15. North America Pharmacovigilance and Drug Safety Software Market by Functionality: Drug Safety Audits Software, 2021-2031, $ mn
Figure 16. North America Pharmacovigilance and Drug Safety Software Market by Functionality: Issue Tracking Software, 2021-2031, $ mn
Figure 17. North America Pharmacovigilance and Drug Safety Software Market by Functionality: Fully Integrated Software, 2021-2031, $ mn
Figure 18. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase, 2021-2031, % of Sales Revenue
Figure 19. North America Addressable Market Cap in 2022-2031 by Clinical Phase, Value ($ mn) and Share (%)
Figure 20. North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Pre-clinical, 2021-2031, $ mn
Figure 21. North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Phase I, 2021-2031, $ mn
Figure 22. North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Phase II, 2021-2031, $ mn
Figure 23. North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Phase III, 2021-2031, $ mn
Figure 24. North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Phase IV, 2021-2031, $ mn
Figure 25. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by Method, 2021-2031, % of Sales Revenue
Figure 26. North America Addressable Market Cap in 2022-2031 by Method, Value ($ mn) and Share (%)
Figure 27. North America Pharmacovigilance and Drug Safety Software Market by Method: Spontaneous Reporting, 2021-2031, $ mn
Figure 28. North America Pharmacovigilance and Drug Safety Software Market by Method: Intensified ADR Reporting, 2021-2031, $ mn
Figure 29. North America Pharmacovigilance and Drug Safety Software Market by Method: Targeted Spontaneous Reporting, 2021-2031, $ mn
Figure 30. North America Pharmacovigilance and Drug Safety Software Market by Method: Cohort Event Monitoring, 2021-2031, $ mn
Figure 31. North America Pharmacovigilance and Drug Safety Software Market by Method: EHR Mining, 2021-2031, $ mn
Figure 32. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by Delivery Mode, 2021-2031, % of Revenue
Figure 33. North America Addressable Market Cap in 2022-2031 by Delivery Mode, Value ($ mn) and Share (%)
Figure 34. North America Pharmacovigilance and Drug Safety Software Market by Delivery Mode: On-premise Delivery, 2021-2031, $ mn
Figure 35. North America Pharmacovigilance and Drug Safety Software Market by Delivery Mode: On-demand Delivery, 2021-2031, $ mn
Figure 36. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by Indication, 2021-2031, % of Revenue
Figure 37. North America Addressable Market Cap in 2022-2031 by Indication, Value ($ mn) and Share (%)
Figure 38. North America Pharmacovigilance and Drug Safety Software Market by Indication: Oncology, 2021-2031, $ mn
Figure 39. North America Pharmacovigilance and Drug Safety Software Market by Indication: Respiratory Disorders, 2021-2031, $ mn
Figure 40. North America Pharmacovigilance and Drug Safety Software Market by Indication: Cardiology, 2021-2031, $ mn
Figure 41. North America Pharmacovigilance and Drug Safety Software Market by Indication: Neurology, 2021-2031, $ mn
Figure 42. North America Pharmacovigilance and Drug Safety Software Market by Indication: Immunology, 2021-2031, $ mn
Figure 43. North America Pharmacovigilance and Drug Safety Software Market by Indication: Pain Management, 2021-2031, $ mn
Figure 44. North America Pharmacovigilance and Drug Safety Software Market by Indication: Other Indications, 2021-2031, $ mn
Figure 45. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by End User, 2021-2031, % of Revenue
Figure 46. North America Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%)
Figure 47. North America Pharmacovigilance and Drug Safety Software Market by End User: Pharmaceutical and Biotechnology Companies, 2021-2031, $ mn
Figure 48. North America Pharmacovigilance and Drug Safety Software Market by End User: Contract Research Organizations (CROs), 2021-2031, $ mn
Figure 49. North America Pharmacovigilance and Drug Safety Software Market by End User: Business Process Outsourcing Firms (BPOs), 2021-2031, $ mn
Figure 50. North America Pharmacovigilance and Drug Safety Software Market by End User: Other End Users, 2021-2031, $ mn
Figure 51. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by Country, 2021 and 2031, % of Revenue
Figure 52. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 53. U.S. Pharmacovigilance and Drug Safety Software Market, 2021-2031, $ mn
Figure 54. Canada Pharmacovigilance and Drug Safety Software Market, 2021-2031, $ mn
Figure 55. Pharmacovigilance and Drug Safety Software Market in Mexico, 2021-2031, $ mn
Figure 56. Growth Stage of North America Pharmacovigilance and Drug Safety Software Industry over the Forecast Period